The vascular endothelial growth factor receptor inhibitor PTK787/ZK222584 inhibits aromatase

Cancer Research

Volumn 69, Issue 11, 2009, Pages 4716-4723

  Banerjee, Susana ^a   Zvelebil, Marketa ^a   Furet, Pascal ^c   Mueller Vieira, Ursula ^d   Evans, Dean B ^c   Dowsett, Mitch ^b   Martin, Lesley Ann ^a  

^a INSTITUTE OF CANCER RESEARCH   (United Kingdom)

^b ROYAL MARSDEN HOSPITAL   (United Kingdom)

^c NOVARTIS PHARMA AG   (Switzerland)

^d Pharmacelsus GmbH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANDROSTENEDIONE; AROMATASE; ESTRADIOL; ESTROGEN RECEPTOR; VASCULOTROPIN RECEPTOR; VATALANIB;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; CONTROLLED STUDY; DRUG PROTEIN BINDING; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOLECULAR MODEL; PRIORITY JOURNAL;

ANGIOGENESIS INHIBITORS; AROMATASE; AROMATASE INHIBITORS; CELL PROLIFERATION; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; ESTRADIOL; HUMANS; MODELS, MOLECULAR; PHTHALAZINES; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTORS, ESTROGEN; RECEPTORS, VASCULAR ENDOTHELIAL GROWTH FACTOR; SUBSTRATE SPECIFICITY; TRANSCRIPTION, GENETIC; TUMOR CELLS, CULTURED;

EID: 66349084100     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-08-4711     Document Type: Article

References (27)

1. Smith IE, Dowsett M. Aromatase inhibitors in breast cancer. N Engl J Med 2003;348:2431-2442 (Pubitemid 36682823)
2. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 2005;97:1262-1271 (Pubitemid 41535367)
3. Howell A, Cuzick J, Baum M, et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 2005;365:60-62 (Pubitemid 40082147)
4. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial. Lancet 2007;369:559-570 (Pubitemid 46251559)
5. Johnston SR, Head J, Pancholi S, et al. Integration of signal transduction inhibitors with endocrine therapy: an approach to overcoming hormone resistance in breast cancer. Clin Cancer Res 2003;9:524-32S. (Pubitemid 36105797)
6. Schiff R, Massarweh SA, Shou J, Bharwani L, Mohsin SK, Osborne CK. Cross-talk between estrogen receptor and growth factor pathways as a molecular target for overcoming endocrine resistance. Clin Cancer Res 2004;10:331-6S. (Pubitemid 38116639)
7. Banerjee S, Dowsett M, Ashworth A, Martin LA. Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol 2007;4:536-550
8. Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev 2008;29:217-233
9. Ryden L, Jirstrom K, Bendahl PO, et al. Tumor-specific expression of vascular endothelial growth factor receptor 2 but not vascular endothelial growth factor or human epidermal growth factor receptor 2 is associated with impaired response to adjuvant tamoxifen in premenopausal breast cancer. J Clin Oncol 2005;23:4695-4704 (Pubitemid 46224072)
10. Wood JM, Bold G, Buchdunger E, et al. PTK787/ZK 222584, a novel and potent inhibitor of vascular endothelial growth factor receptor tyrosine kinases, impairs vascular endothelial growth factor-induced responses and tumor growth after oral administration. Cancer Res 2000;60:2178-2189 (Pubitemid 30225181)
11. Macaulay VM, Nicholls JE, Gledhill J, Rowlands MG, Dowsett M, Ashworth A. Biological effects of stable overexpression of aromatase in human hormone-dependent breast cancer cells. Br J Cancer 1994;69:77-83. (Pubitemid 24021826)
12. Martin LA, Pancholi S, Chan CM, et al. The anti-oestrogen ICI 182,780, but not tamoxifen, inhibits the growth of MCF-7 breast cancer cells refractory to long-term oestrogen deprivation through down-regulation of oestrogen receptor and IGF signalling. Endocr Relat Cancer 2005;12:1017-1036 (Pubitemid 41815794)
13. Thompson EA, Jr., Siiteri PK. Utilization of oxygen and reduced nicotinamide adenine dinucleotide phosphate by human placental microsomes during aromatization of androstenedione. J Biol Chem 1974;249:5364-5372
14. Eng ET, Ye J, Williams D, et al. Suppression of estrogen biosynthesis by procyanidin dimers in red wine and grape seeds. Cancer Res 2003;63:8516-8522 (Pubitemid 37549510)
15. Bradford MM. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 1976;72:248-254
16. Verdonk ML, Cole JC, Hartshorn MJ, Murray CW, Taylor RD. Improved protein-ligand docking using GOLD. Proteins 2003;52:609-623 (Pubitemid 37034158)
17. Furet P, Batzl C, Bhatnagar A, Francotte E, Rihs G, Lang M. Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds. J Med Chem 1993;36:1393-1400 (Pubitemid 23164496)
18. McNeil C. Two targets, one drug for new EGFR inhibitors. J Natl Cancer Inst 2006;98:1102-1103
19. Geyer CE, Forster J, Lindquist D, et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733-2743 (Pubitemid 46021510)
20. Foster PA, Chander SK, Newman SP, et al. A new therapeutic strategy against hormone-dependent breast cancer: the preclinical development of a dual aromatase and sulfatase inhibitor. Clin Cancer Res 2008;14:6469-6477
21. Karaman MW, Herrgard S, Treiber DK, et al. A quantitative analysis of kinase inhibitor selectivity. Nat Biotechnol 2008;26:127-132
22. Ghosh D, Griswold J, Erman M, Pangborn W. Structural basis for androgen specificity and oestrogen synthesis in human aromatase. Nature 2009;457:219-223
23. Morgan B, Thomas AL, Drevs J, et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK222584 , an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol 2003;21:3955-3964 (Pubitemid 46606209)
24. Los M, Roodhart JM, Voest EE. Target practice: lessons from phase III trials with bevacizumab and vatalanib in the treatment of advanced colorectal cancer. Oncologist 2007;12:443-450 (Pubitemid 46698722)
25. George D OW, Gilligan T, Masson E, et al. Phase I study of the novel, oral angiogenesis inhibitor PTK787/ZK22584 (PTK/ZK): evaluating the pharmacokinetic effect of a high-fat meal in pateints with hormone-refractory prostate cancer. J Clin Oncol, ASCO Annual Meeting Proceedings 2004;22:4689.
26. Joensuu H, De Braud F, Coco P, et al. Phase II, open-label study of PTK787/ZK222584 for the treatment of metastatic gastrointestinal stromal tumors resistant to imatinib mesylate. Ann Oncol 2008;19:173-177
27. Chen S, Zhang F, Sherman MA, et al. Structure-function studies of aromatase and its inhibitors: a progress report. J Steroid Biochem Mol Biol 2003;86:231-237 (Pubitemid 37412562)